Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 10 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
977Linked to a medicine page here

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
  • Recommended: the NHS in England should fund it for the use it is licensed for.
  • Optimised: recommended, but for a narrower group of patients than the licence covers.
  • Cancer Drugs Fund / Innovative Medicines Fund: funded for a limited period while more evidence is collected.
  • Only in research: to be used only as part of a study.
  • Not recommended: NICE decided the NHS should not fund it for this use.
  • Terminated: the company did not send evidence, so NICE could not make a recommendation.

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Appraisals matching “Lenalidomide”

18 appraisals, newest first
AppraisalMedicine pageNICE recommendationPublishedStatus
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
NICE TA1170
DaratumumabOptimised24 Jun 2026Current
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
NICE TA917
DaratumumabRecommended25 Oct 2023Current
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA883
TafasitamabNot recommended3 May 2023Current
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
NICE TA870
IxazomibOptimised22 Feb 2023Current
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)
NICE TA774
LenalidomideTerminated (no company submission)9 Mar 2022Current
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
NICE TA695
CarfilzomibOptimised28 Apr 2021Current
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
NICE TA680
LenalidomideOptimised3 Mar 2021Current
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)
NICE TA634
DaratumumabTerminated (no company submission)30 Jun 2020Current
Lenalidomide with rituximab for previously treated follicular lymphoma
NICE TA627
LenalidomideRecommended7 Apr 2020Current
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)
NICE TA603
LenalidomideTerminated (no company submission)25 Sep 2019Current
Lenalidomide plus dexamethasone for previously untreated multiple myeloma
NICE TA587
LenalidomideOptimised26 Jun 2019Current
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
NICE TA586
LenalidomideOptimised26 Jun 2019Current
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
NICE TA505
IxazomibOptimised (Cancer Drugs Fund)7 Feb 2018Current
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA454
DaratumumabTerminated (no company submission)5 Jul 2017Current
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
NICE TA427
PomalidomideRecommended11 Jan 2017Current
Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
NICE TA338
PomalidomideNot recommended25 Mar 2015Current
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
NICE TA322
LenalidomideRecommended24 Sep 2014
Updated 26 Jun 2019
Current
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
NICE TA171
LenalidomideRecommended18 Jun 2009
Updated 26 Jun 2019
Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 10 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.